发明公开
EP3035956A2 BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF
审中-公开
双特异性双抗体MONO VALENTE与能力GPA33结合和其用途和CD3
- 专利标题： BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF
- 专利标题（中）： 双特异性双抗体MONO VALENTE与能力GPA33结合和其用途和CD3
-
申请号： EP14837376.4申请日： 2014-08-20
-
公开(公告)号： EP3035956A2公开(公告)日： 2016-06-29
- 发明人: MOORE, Paul A. , LI, Jonathan , CHEN, Francine Zhifen , JOHNSON, Leslie S. , SHAH, Kalpana , BONVINI, Ezio
- 申请人： MacroGenics, Inc.
- 申请人地址： 9640 Medical Center Drive Rockville, MD 20850 US
- 专利权人： MacroGenics, Inc.
- 当前专利权人： MacroGenics, Inc.
- 当前专利权人地址： 9640 Medical Center Drive Rockville, MD 20850 US
- 代理机构： Atkinson, Jennifer
- 优先权： US201361869528P 20130823; US201361907691P 20131122; EP13198859 20131220
- 国际公布： WO2015026894 20150226
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; C12P21/08 ; C07K16/00
摘要：
The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a "gpA33 x CD3 bi-specific monovalent diabody"). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc domain ("bi-specific monovalent Fc diabodies") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 ( i.e ., a "gpA33 x CD3 bi-specific monovalent Fc diabody"). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.
公开/授权文献
信息查询
